
A meta-analysis of 4 RCTs (4,092 patients) compared OAC monotherapy with OAC plus SAPT in atrial fibrillation (AF) and stable coronary artery disease (CAD). Results showed no significant differences in ischemic events between groups, but OAC monotherapy reduced the risk of major bleeding (3.3% vs 5.7%; HR: 0.59). Subgroup analyses indicated greater bleeding reduction among men and patients with diabetes.
Like
Save
Share